Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)

EXCELLENT was a prospective, multicenter, randomized, double-blind, placebo-controlled clinical study in which participants were randomized participants were randomized (1:1) to receive either IV thrombolysis + edaravone or IV thrombolysis + matched placebo (same volume of tablets without drug components), and the primary outcome was the proportion of patients with transformed bleeding on MRI at 72 hours following revascularization therapy.

NCT Number	NCT07119021
Lead Sponsor	Ruijun Ji Collaborators: Xing'an League People's Hospital, Suzhou First People's Hospital, Nanyang Nanshi Hospital, Nanjing Baixinyu Pharmaceutical Co., Ltd.
Conditions	Ischemic Stroke
Enrollment	300 participants
Start Date	2024-08-01
Primary Completion	2027-04-30 (estimated)
Study Completion	2027-07-31 (estimated)
Updated on ClinicalTrials.gov	2025-08-12